Wednesday, August 31, 2005

Biogen seeks stronger Tysabri label warning

The head of Biogen Idec says his company will recommend a stronger warning label for a multiple sclerosis drug it hopes to return to the market. James Mullen, Biogen's chief executive and president, told The Associated Press today that the company will recommend that regulators include a warning about Tysabri's link to a rare but often-fatal brain disease.

technorati tags: ,

No comments: